Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexFemale
Age18-39
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
The development of stimulation protocols for in vitro fertilisation (IVF) has led to a paradox. It has now been established that obtaining a large number of oocytes is a key to success, but that it is also a risk factor for embryo transfer failure after puncture (disruption of endometrial receptivity due to luteal insufficiency) and a risk factor for complications such as ovarian hyperstimulation syndrome (OHSS).
Eligibility criteria
Qualifiers
Patients requiring conventional IVF or IVF with sperm injection (ICSI) from the partner or donor under the conditions of management defined by French law.
Patients aged 18 to 39 included
First or second attempt at IVF or ICSI for pregnancy
BMI < 35 kg/m2
Disqualifiers
Patient diagnosed with HIV infection
ICSI with sperm from testicular biopsy
Pre-implantation diagnosis
Hypogonadotropic hypogonadism (amenorrhea or spaniomenorrhea with basal LH <1.2 IU/L)
Trial design
Treatments tested in this trial
- Ovulation induction with hCG + Luteal phase support with vaginal progesterone
- Ovulation triggering by Triptorelin + Luteal phase support by Nafarelin
Treatment groups
652 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov